Advances in the Treatment of Lung Cancer
David P. Carbone, MD, PhD, from the The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
David P. Carbone, MD, PhD, Professor, Division of Medical Oncology, Director, Thoracic Oncology Center, The James, The Ohio State University Wexner Medical Center, discusses advances in the treatment of lung cancer.
Recent advances in immunotherapy of lung cancer are probably the most exciting aspect of lung cancer therapy in the last few years, Carbone says. There is a large portion of patients who do not have immediately actionable lesions identified by current gene sequencing methods. Immunotherapy is potentially effective in these patients and could provide a way to improve outcome even in patients with EGFR and ALK mutations in combination with other treatments.
Clinical Pearls
- A large portion of the patient population does not have immediately actionable lesions identified by current gene sequencing methods
- Immunotherapy is potentially effective for this group of patients
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Kim Evaluates New Regimens for EGFR+ Lung Cancer
January 20th 2025During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S. Kim, MD, MBA, discussed the FLAURA2 and MARIPOSA trials of newer regimens for EGFR-positive lung cancer.
Read More
